Markus Jönsson appointed new CEO, takes office 1 October. Solid experience within industrial biotech and speciality chemicals. Vision to broaden the company's portfolio.
ECHA's BPC adopts opinion that Medetomidine has ED properties. European Commission now to decide on potential exception. We believe case for exception good, EU only 10% of market.
Japanese sales SEK 29m during first half of 2024, +96% y-o-y. Growth driven by largest customer CMP and Kansai Paints Marine. Continued Japanese interest in Selektope, 44% 3y-volume CAGR.
Q1: sales SEK 38m, +24% y-o-y; adj. EBIT margin of 27% (27%). Demonstrated Q4 was temporary setback, long-term potential intact. Costs associated with EU regulatory process to persist in '24.